Prevention of Organ Dysfunction and Mortality by Monitoring the Administration of Opioids and Hypnotics in Patients at High Postoperative Risk: the Opti-Two Study. A Multi-center Controlled Randomized Study.

Status: Recruiting
Location: See all (14) locations...
Intervention Type: Procedure
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Intraoperative hypotension is a common situation. It increases postoperative morbidity and mortality, especially in patients at high postoperative risk undergoing high-risk surgery. Intraoperative hypotension is partly related to anesthesia, and mainly to the combined, dose-dependent, synergistic effect of hypnotics and opioids. Monitoring sedation and monitoring analgesia reduce intraoperative consumption of each anesthetic agent. To date, the beneficial effect of combined sedation and analgesia monitoring on the reduction of intraoperative hypotension has only been found in one study, involving major abdominal surgery. Up to now, no study has been designed to demonstrate the benefit of monitoring the two components of anesthesia on postoperative organ dysfunction and mortality. The study propose to evaluate the relevance of a combined optimization of hypnotic and opioid agents on the most frequently encountered dysfunctions related to intraoperative hypotension.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 75
Healthy Volunteers: f
View:

• patients affiliated to the French Social Security;

• informed and signed consent to participating in the study;

• planned postoperative hospitalization \> 48 hours;

• patients over 75 years of age with at least one of the following postoperative risk factors:

‣ ischemic coronary disease;

⁃ history of compensated or prior heart failure;

⁃ stroke;

⁃ significant arrhythmias: fibrillation or auricular flutter with ventricular response \> 100/minute, multiform QRS complex) or cardiac conduction abnormalities (trifascicular block, auriculoventricular block of the second or third degree);

⁃ peripheral vascular disease;

⁃ chronic obstructive pulmonary disease;

⁃ chronic respiratory failure;

⁃ renal insufficiency, defined by a creatinine \> 175 µmol.l-1 (2 mg.dl-1);

⁃ insulin therapy for diabetes;

⁃ active cancer;

⁃ chronic alcohol abuse;

⁃ dementia.

• elective or emergency high-risk surgery under general anesthesia with a combination of hypnotic and opioid, and intubation or placement of a supraglottic airway control device:

∙ Non inclusion criteria:

• Patients who meet one or more of the preoperative following criteria will not be included:

• acute heart failure or acute myocardial infarction;

• acute respiratory failure or pneumonia;

• septic shock;

• acute stroke;

• cardiac surgery;

• open chest surgery;

• opioid free anesthesia;

• intraoperative ketamine at a dose \> 0.2 mg.kg-1;

• lidocaine or dexmedetomidine by continuous infusion;

• refusal to participate in the study;

Locations
Other Locations
France
Chu D'Amiens Picardie
NOT_YET_RECRUITING
Amiens
Chru de Besancon
NOT_YET_RECRUITING
Besançon
Chu Clermont-Ferrand
NOT_YET_RECRUITING
Clermont-ferrand
Chu de Grenoble
NOT_YET_RECRUITING
Grenoble
Chu de Lille
NOT_YET_RECRUITING
Lille
APHM - Centre Hôpital Marseille Nord
NOT_YET_RECRUITING
Marseille
Chu de Nantes
NOT_YET_RECRUITING
Nantes
Chu de Nimes
NOT_YET_RECRUITING
Nîmes
Hopital Bichat Claude Bernard
NOT_YET_RECRUITING
Paris
Chu Lyon Sud
NOT_YET_RECRUITING
Pierre-bénite
Chu de Poitiers
NOT_YET_RECRUITING
Poitiers
Chu St-Etienne
RECRUITING
Saint-etienne
Chu de Toulouse
NOT_YET_RECRUITING
Toulouse
Médipole Lyon Villeurbanne
NOT_YET_RECRUITING
Villeurbanne
Contact Information
Primary
David CHARIER, MD
david.charier@chu-st-etienne.fr
+33.4.77.82.85.65
Backup
Carine LABRUYERE, CRA
carine.labruyere@chu-st-etienne.fr
+33.4.77.12.04.69
Time Frame
Start Date: 2023-10-12
Estimated Completion Date: 2027-12
Participants
Target number of participants: 1132
Treatments
Experimental: Intervention Group
Placebo_comparator: Control Group
Related Therapeutic Areas
Sponsors
Leads: Centre Hospitalier Universitaire de Saint Etienne
Collaborators: Direction Générale de l'Offre de Soins

This content was sourced from clinicaltrials.gov